Please use this identifier to cite or link to this item:
|Title:||Cyclo (Nα-dinicotinoyl)-bis-[(L-valinyl)-L-lysinyl acid hydrazide]: Assessment of its Role in Cancer and Kinase Activity Inhibition|
|Authors:||Amr, A E|
Elsayed, E A
Al-Omar, M A
Almehizia, A A
Abdel-Mageid, Randa E.
|Keywords:||Anticancer;Synthesis;Peptides;Hydrazide;Mechanism of action|
|Abstract:||Current research aimed at evaluating the in vitro as well as in vivo anticancer activities of a newly synthesized peptide hydrazide; i.e. 4,14-diisopropyl-2,5,13,16-tetraoxo-3,6,12,15-tetraaza-1(3,5)-pyridinacyclohexadecaphane-7-carbohydrazide. The hydrazide was synthesized from methyl 4,14-diisopropyl-2,5,13,16-tetraoxo-3,6,12,15-tetraaza-1(3,5)-pyridinacyclohexadecaphane-7-carboxylate 2 by acting of hydrazine hydrate. It showed significant anticancer effects against different tested cell lines, where cervical, breast, liver, colon, prostate, brain, fibrosarcoma, leukemia and melanoma cell lines were the most affected cell types. The prepared derivative also inhibited VEGF-2 kinase enzyme significantly and exhibited an in vivo tumorigenic effects in mice model.|
|ISSN:||0975-1084 (Online); 0022-4456 (Print)|
|Appears in Collections:||JSIR Vol.79(04) [April 2020]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.